Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Return on Sales (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Return on Sales for 6 consecutive years, with 0.05% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales rose 8101.0% year-over-year to 0.05%, compared with a TTM value of 5.5% through Sep 2025, up 6083.0%, and an annual FY2024 reading of 46.7%, up 8682.0% over the prior year.
  • Return on Sales was 0.05% for Q3 2025 at Ovid Therapeutics, up from 0.75% in the prior quarter.
  • Across five years, Return on Sales topped out at 50.42% in Q2 2024 and bottomed at 1077.98% in Q3 2022.
  • Average Return on Sales over 5 years is 89.84%, with a median of 0.23% recorded in 2023.
  • The sharpest move saw Return on Sales crashed -107858bps in 2022, then surged 97474bps in 2023.
  • Year by year, Return on Sales stood at 0.59% in 2021, then tumbled by -109bps to 0.05% in 2022, then crashed by -354bps to 0.23% in 2023, then plummeted by -51721bps to 121.75% in 2024, then skyrocketed by 100bps to 0.05% in 2025.
  • Business Quant data shows Return on Sales for OVID at 0.05% in Q3 2025, 0.75% in Q2 2025, and 0.05% in Q1 2025.